semaglutide loss of exclusivity sales hit $26 billion, but looms | IQVIA posted on the topic Maximizing GLP-1 Market Exclusivity: Leveraging

As your dose evolves, optimizing your food choices ensures you feel your best and see the results you're working toward

The control group comprised 61 patients and the remission group consisted of 35 patients who achieved remission

Glucagon-like peptide1 analogues for type 2 diabetes mellitus

The Phase 2 trial data showed nausea in roughly 28% of patients at the 12mg dose, diarrhea in 24%, vomiting in 17%, and constipation in 11%

As part of this initiative, our team had the opportunity to support the study comprehensively across its full lifecyclereinforcing the value of rigorous late-phase research in real-world clinical environments